Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Operating expense | 11M | 23.3% |
| Net Income | -9.9M | 27.5% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 89M | 5.8% |
| Total Liabilities | 8.8M | 2.9% |
| Total Equity | 80M | 6.6% |
| Shares Outstanding | 74M | 17% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -5.6M | 35.8% |
| Cash from financing | 32,000 | 0% |
EPS
Financial Highlights for Inhibikase Therapeutics in Q2 '25
Operating Expenses for this period were 11M, showing a -23.3% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -9.9M, showing a 27.5% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's performance remained stable this quarter with no significant positive or negative changes in the key financial metrics.
